Abstract:Diseases caused by human herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) affect millions of people worldwide and range from fatal encephalitis in neonates and herpes keratitis to orofacial and genital herpes, among other manifestations. The viruses can be shed efficiently by asymptomatic carriers, causing increased rates of infection. Viral transmission occurs through direct contact of mucosal surfaces followed by initial replication of the incoming virus in skin tissues. Subsequently, the viruses infect sensory neurons in the trigeminal and lumbosacral dorsal root ganglia, where they are primarily maintained in a transcriptionally repressed state termed "latency", which persists for the lifetime of the host. HSV DNA has also been detected in other sympathetic ganglia. Periodically, latent viruses can reactivate, causing ulcerative and often painful lesions primarily at the site of primary infection and proximal sites. In the United States, recurrent genital herpes alone accounts for more than a billion dollars in direct medical costs per year, while there are much higher costs associated with the socio-economic aspects of diseased patients, such as loss of productivity due to mental anguish. Currently, there are no effective FDA-approved vaccines for either prophylactic or therapeutic treatment of human herpes simplex infections, while several recent clinical trials have failed to achieve their endpoint goals. Historically, live-attenuated vaccines have successfully combated viral diseases, including polio, influenza, measles, and smallpox. Vaccines aimed to protect against the devastation of smallpox led to the most significant achievement in medical history: the eradication of human disease by vaccination. Recently, novel approaches toward developing safe and effective live-attenuated vaccines have demonstrated high efficacy in various preclinical models of herpetic disease. This next generation of live-attenuated vaccines has been tailored to minimize vaccine-associated side effects and promote effective and long-lasting immune responses. The ultimate goal is to prevent or reduce primary infections (prophylactic vaccines) or reduce the frequency and severity of disease associated with reactivation events (therapeutic vaccines). These vaccines' "rational" design is based on our current understanding of the immunopathogenesis of herpesviral infections that guide the development of vaccines that generate robust and protective immune responses. This review covers recent advances in the development of herpes simplex vaccines and the current state of ongoing clinical trials in pursuit of an effective vaccine against herpes simplex virus infections and associated diseases.

Therapeutic vaccines for herpesviruses

[Mechanisms of Herpes Simplex Virus Latency and Reactivation].

Broadly Reactive Human CD8 T Cells that Recognize an Epitope Conserved between VZV, HSV and EBV

Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses

Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond

Clinical management of herpes simplex virus infections: past, present, and future

Recent Advances in the Study of Alphaherpesvirus Latency and Reactivation: Novel Guidance for the Design of Herpesvirus Live Vector Vaccines

Immune Response to Herpes Simplex Virus Infection and Vaccine Development

Status Quo of the Researches on HSV Vaccines

Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents

Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV)

Clinical Features of Varicella-Zoster Virus Infection

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

Molecular studies of Varicella zoster virus

Molecular Aspects of Varicella-Zoster Virus Latency

A review of HSV pathogenesis, vaccine development, and advanced applications

Efficacy of varicella (VZV) vaccination: an update for the clinician

The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors

Advances and Perspectives in the Management of Varicella-Zoster Virus Infections

Treatment of Epstein-Barr Virus infection in immunocompromised patients

Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections